The Clinical Investigation of Mycophenolate Mofetil for the Prevention of Acute Rejection
- VernacularTitle:霉酚酸酯预防肾移植术后急性排斥反应临床观察
- Author:
Yulian JI
;
Yanqiang YANG
;
Guangbao YANG
;
Xueqing YU
;
Zongpei JIANG
;
Qingrui SHEN
;
Peigen WU
;
Lanying ZHU
- Publication Type:Journal Article
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2001;22(3):215-217
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】To investigate the role of mycophenolate mofetil (MMF) in the prevention of acute rejection in renal transplantation.【Methods】A total of 106 patients were randomized into two groups.One group received MMF (n=56),the other received azathioprine (Aza) (n=50).The time of the following study was within the first 6 months after transplantation.【Results】The rate of acute rejection of group receiving MMF was 20%,it′s lower than that of the group receiving Aza 44% (P<0.01).The recovery rate of acute rejection treated by methylprednisolone (MP),in MMF group 82% was higher than Aza group 55%.(P<0.05).Meanwhile the hepatotoxicity as well as cytomegalovirus (CMV) infection were lower in MMF group than those in Aza group.【Conclusion】MMF as a new anti-rejection drug could more effectively prevent acute rejection than Aza after renal transplantation,and has lower toxicity and side effect.
